RxDoctor Payments Data

Nirav Patel, MD

Cardiovascular Disease · Jackson, TNNPI 1790907418

Payments from drug & device makers

$12,404in general payments, 2019–2025

Across 224 payments — averaging $55.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • E.r. Squibb & Sons, L.L.C.$8K
  • Angiodynamics, Inc.$1K
  • Boston Scientific$798
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$729
  • Johnson & Johnson$310
  • Abbott$216
  • plus $1K from 20 others

What the payments were for

  • Consulting fees$6,16550%
  • Travel & lodging$7566%
  • Food & beverage$5,48244%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,404 in reported general payments places this provider in the 75th percentile of 429 cardiovascular disease providers in Tennessee.

See all cardiovascular disease providers in Tennessee

Medicare billing

Part B allowed, 2024
$1,282,208
Medicare patients
1,299
Services billed
14,688

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban268$214,295
EntrestoSacubitril/Valsartan197$163,550
XareltoRivaroxaban89$60,281
FarxigaDapagliflozin Propanediol69$50,615
BrilintaTicagrelor97$50,279
Repatha SureclickEvolocumab35$28,468
JardianceEmpagliflozin26$18,502
Ranolazine ErRanolazine61$5,431
ClopidogrelClopidogrel Bisulfate549$5,380
Atorvastatin Calcium320$3,746
Metoprolol Tartrate313$2,262
Ezetimibe85$2,078
Carvedilol290$1,794
Valsartan13$1,616
Isosorbide Mononitrate ErIsosorbide Mononitrate138$1,538

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$140$214,295268 claims
NovartisEntresto$82$163,550197 claims
AstraZenecaFarxiga, Brilinta$13$100,894166 claims
Johnson & JohnsonXarelto$310$60,28189 claims
Boehringer IngelheimJardiance$14$18,50226 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 429 cardiovascular disease providers in Tennessee.

Other cardiovascular disease in Jackson

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →